Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: Sequenom; Arrayjet; Population Genetics Technologies; Protea Biosciences; Assay Depot, Rare Genomics Institute

NEW YORK (GenomeWeb News) – Sequenom said this week that the California Technology Assessment Forum has completed an independent evaluation of the cell-free fetal DNA technology used in the Sequenom Center for Molecular Medicine's MaterniT21 Plus laboratory-developed test. According to the firm, CTAF recommended that the use of cell-free fetal DNA as a prenatal advanced screening test for fetal aneuploidy for Trisomy 21 and Trisomy 18 in high-risk women meets all five CTAF criteria for safety and efficacy and improvement in health outcomes.

CTAF is an independent medical technology assessment organization that was established to assess new medical technologies. It is spearheaded by the Blue Shield of California Foundation.

Edinburgh, UK-based Arrayjet has opened a US office in Cambridge, Mass. The maker of inkjet microarrayers said that the new office was in response to increased demand for its products in North America.

Cambridge, UK-based Population Genetics Technologies this week launched a competition for its Populus Award 2012. The competition seeks research proposals from researchers conducting population genetics studies and will provide funding and practical support for sequencing studies, as well as access to Population Genetics' expertise and proprietary technologies, including its three different propriety technologies that it uses to prepare large numbers of samples for sequencing — GenomePooling, Reflex, and VeriTag.

For more information on the contest, see this article GenomeWeb Daily News sister publication In Sequence.

Protea Biosciences this week said that it has opened a Mass Spectrometry Imaging Center in Morgantown, WV. The Chicago-based firm said that the new center will offer access to advanced biomolecular imaging capabilities through the combination of ultra-high-resolution mass spectrometry with its own LAESI (Laser Ablation Electrospray Ionization) platform.

Assay Depot and the Rare Genomics Institute said this week that they have partnered with 19 life science companies to launch the first Rare Disease Science Challenge. The hosts and sponsoring organizations are supporting rare disease research with $400,000 in cutting-edge technologies and a $10,000 cash prize for the winning research proposal. Among the sponsors are Charles River Laboratories, DNA Software, HistoRx, and Ingenuity Systems.

Proposals can be submitted between Oct. 15 and Dec. 15.

More on the challenge can be found here.

In Brief This Week is a Friday column containing news items that our readers may have missed during the week.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.